S. 3788 · 119th Congress · Health
CLEAR LABELS Act
Requires drug labels to list manufacturers' names and locations. AI-read
- IntroducedFeb 5, 2026 Done
- CommitteeReported Jul 27, 2026 Done
- Senate floorAwaiting vote Current stage
- House floorNot yet Not reached yet
- Chambers agreeNot yet Not reached yet
- PresidentNot yet Not reached yet
What it does
This bill requires drugs and active pharmaceutical ingredients made available in the U.S. market to be labeled with the names and locations of their manufacturers.
Specifically, a finished, packaged drug product must be labeled with the name and place of business of (1) the original manufacturer (or manufacturers) of each active pharmaceutical ingredient; (2) the original manufacturer of the finished drug product; and (3) the packer or distributor, if any. This information must be printed on the product label or made available electronically. Active pharmaceutical ingredients (which are generally sold to manufacturers and researchers, not consumers) must also be labeled with the name and place of business of their original manufacturers.
Under the bill, the original manufacturer is the establishment that conducts the majority of the significant phases of manufacturing to produce the ingredient or product.
The Food and Drug Administration (FDA) has discretion to determine whether a violation of these requirements constitutes misbranding and to assess a civil fine. The FDA must consider certain factors in determining whether to assess a fine, including whether the violator was notified of their noncompliance and was provided an opportunity to correct the violation.
Finally, the FDA must coordinate with U.S. Customs and Border Protection to address any overlap between these requirements and existing requirements for imported drugs.
These provisions take effect five years after the bill is enacted.
Congressional Research Service · summary of “Reported to Senate” version · Jul 27, 2026
Who lobbies on it
10 organizations, more than 96% of Senate bills · 29 filings · Q1 2026–Q3 2026These 10 organizations’ PACs gave $63K to 7 of the 12 members sponsoring or cosponsoring S. 3788 in the 2025–26 election cycle.
One square per quarter since introduction, oldest left. Filled = named it that quarter.
-
Pharmaceutical Research and Manufacturers of America
3 of 3 quarters
“…S. 3788: CLEAR LABELS Act S. 3794: SAFE Drugs Act of 2026 S. 4189: INSULIN Act of 2026 S. 5043: Secure Drug Supply Chain Act of 2026 S. 5244: SUSTAIN 340B Act H.R. 1: One Big Beautiful Bill Act (Public Law 119-21) H.R. 946: ORPHAN Cures Act H.R. 1492: To amend title XI of the Social Security Act to equalize the…”
$26.6M lobbying spend in 2026 to date, all issuesQ3 2026 filing
-
Amgen
3 of 3 quarters
“Issues related to pharmacy benefit management reforms. Issues related to cardiovascular care. Issues related to drug pricing. Issues related to the drug supply chain. S. 3788, Clear Labels Act. S. 3014, Ensuring Timely Access to Generics Act of 2025; S. 1954, Biosimilar Red Tape Elimination Act; S. 2658, Medication…”
$8.2M lobbying spend in 2026 to date, all issuesQ3 2026 filing
-
Association for Accessible Medicines
3 of 3 quarters
“…S.3788: Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act. American Made Medicines Act. PBM Bid Transparency. S.4280: Security And Freedom Enhancement Act of 2026 (SAFE) Act.”
$2.5M lobbying spend in 2026 to date, all issuesQ3 2026 filing
7 more organizations, every filingPROUpgrade
Organizations that named S. 3788 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. “Gave to” means the organization’s PAC gave to the member’s campaign in the 2025–26 cycle, net of refunds; it doesn’t mean the money was about this bill. Organizations may lobby for, against, or to change a bill; filings don’t say which. Source: Senate lobbying disclosures (LD-2) from lda.gov; PAC gifts from FEC filings; quotes are word for word from the “specific lobbying issues” field; where a filing lists many bills, the quote starts where it names this one.
Actions
6 actions · newest first- Jul 27, 2026Placed on Senate Legislative Calendar under General Orders. Calendar No. 523.
- Jul 27, 2026Committee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute. Without written report.
- Jul 22, 2026Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
- Mar 19, 2026Committee on Health, Education, Labor, and Pensions. Hearings held.
Show all 6 actionsShow fewer
- Feb 5, 2026Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- Feb 5, 2026Introduced in Senate
What members said about it
-
‘A particular brand of evil’: Sen. Rick Scott Leads Senate in Sending Xi Birthday Condemnation
Today, a day after Xi Jinping’s birthday, the U.S. Senate unanimously passed a resolution led by U.S. Senator Rick Scott condemning Xi Jinping, General Secretary of the Chinese Communist Party (CCP), as well as the long train of abuses and…
“The CCP, especially under Xi Jinping’s tyranny, has a particular brand of evil. They seek to control the world, and in their mind, that means destroying anyone who stands in their way – whether it’s their own people or not. We cannot be afraid to stand up to our enemies and hold the line for the next generation of…”